Search / Trial NCT00000244

Effects of Dynorphin 1-13 on Heroin Addiction - 1

Launched by UNIVERSITY OF MINNESOTA · Sep 20, 1999

Apply for Trial

Trial Information

Current as of September 08, 2024

Completed

Keywords

Addiction Opiate Heroin Dynorphin

Description

Randomized double blinded study of the effects of a single IV dose of dynorphin A 1-13 on heroin withdrawal in human opiate addicts

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • opiate addict between the ages of 18-55
  • Exclusion Criteria:
  • Regular abuse of other drugs, unstable medical conditions

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Minneapolis, Minnesota, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0